Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CNR2 | P34972 | 7/20 | 0.51 |
| ▸ | CREBBP | Q92793 | 4/20 | 0.50 |
| ▸ | HRH2 | P25021 | 1/20 | 0.49 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5460523 | 0.94 | CREBBP (0.52) | SMN1; SMN2ALDH1A1KMT2ACNR2CREBBP | |
| SCHEMBL5455228 | 0.88 | CNR2 (0.48) | ALDH1A1CNR2HRH2CNR1MAPT | |
| SCHEMBL5463523 | 0.88 | SMN1; SMN2 (0.53) | SMN1; SMN2ALDH1A1KMT2ACNR2CREBBP | |
| SCHEMBL5445683 | 0.88 | CNR2 (0.47) | ALDH1A1CNR2HRH2CNR1MAPT | |
| SCHEMBL14463865 | 0.86 | SMN1; SMN2 (0.40) | SMN1; SMN2ALDH1A1KMT2ACNR2CREBBP | |
| SCHEMBL5456124 | 0.86 | CNR2 (0.46) | SMN1; SMN2ALDH1A1CNR2HRH2CNR1 | |
| SCHEMBL5452624 | 0.86 | PRPS1 (0.45) | SMN1; SMN2ALDH1A1KMT2ACNR2HRH2 | |
| SCHEMBL5449002 | 0.86 | SMN1; SMN2 (0.51) | SMN1; SMN2ALDH1A1KMT2ACNR2CREBBP | |
| SCHEMBL5448665 | 0.85 | CNR2 (0.49) | SMN1; SMN2ALDH1A1KMT2ACNR2HRH2 | |
| SCHEMBL5451221 | 0.84 | ADRA1D (0.49) | CNR2HRH2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| WO-2007079239-A2 | BICYCLIC NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | SMN1; SMN2 1701/4885ALDH1A1 2963/4885KMT2A 4056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.